Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody

Wang, Chung Hao; Chiou, Shih Hwa; Chou, Chen Pin; Chen, Yu‐Chih; Huang, Yao Jhang; Peng, Ching An

doi:10.1016/j.nano.2010.06.010

Cited by 168 publications

(114 citation statements)

References 27 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…This CSC phenotype may be used as a basis for the specific targeting of CSCs (25). Single-walled carbon nanotubes with CD133 monoclonal antibodies (anti-CD133-SWNTs), developed by Wang et al (26), have been demonstrated to block the tumorigenicity of glioblastoma-CD133 + cells. However, single-walled carbon nanotubes may present risks to human health (27).…”

Section: Discussionmentioning

confidence: 99%

The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles

Huang

Deng

2018

Oncol Lett

View full text Add to dashboard Cite

Abstract. Ovarian cancer is the most lethal gynecologic malignancy, and ovarian cancer stem cells (CSCs) serve a pivotal function in the metastasis and recurrence of ovarian cancer. Multiple previous studies have validated CD133 as a marker of ovarian CSCs. Although salinomycin is a promising therapeutic agent that has been demonstrated to kill CSCs in various types of cancer, poor aqueous solubility hampers its clinical application. The present study used salinomycin-loaded poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles conjugated with CD133 antibodies (CD133-SAL-NP) to eliminate CD133 + ovarian CSCs. The results revealed that CD133-SAL-NPs were of an appropriate size (149.2 nm) and exhibited sustained drug release. CD133-SAL-NPs efficiently bound to CD133 + ovarian cancer cells, resulting in an increased cytotoxic effect in CD133 + ovarian cancer cells, compared with the untargeted SAL-NPs and salinomycin. CD133-SAL-NPs reduced the percentage of CD133 + ovarian CSCs in ovarian cells more effectively than treatment with salinomycin or SAL-NPs, suggesting that CD133-SAL-NP targeted CD133 + ovarian CSCs. In nude mice bearing ovarian cancer xenografts, CD133-SAL-NPs exerted improved therapeutic effects compared with SAL-NPs and salinomycin. Thus, CD133 was demonstrated to be a promising target for drug delivery to ovarian CSCs, and may be useful as an agent to inhibit the growth of ovarian cancer by targeting CD133 + ovarian CSCs. CD133-SAL-NPs may therefore represent a promising approach for the treatment of ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles

Huang

Deng

2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…93 In vitro pretreated with single-walled carbon nanotubes (SWNTs) conjugated with CD133 monoclonal antibody (anti-CD133) and then irradiated with near-infrared laser light, CD133 positive cells in glioblastoma (GBM-CD133 + ), which display cancer stem cell-like characteristics, were selectively targeted and eradicated, whereas CD133 − cells in glioblastoma (GBM-CD133 − ) remained viable. 94 More over, the self-renewal and tumor-initating capability of GBM-CD133 + treated with localized hyperthermia was significantly blocked. 94 In another study, a bispecific EpCAMxCD3 antibody linking tumor cells and T lymphocytes significantly retarded the tumor growth of BxPC-3 pancreatic carcinoma xenografts.…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%

“…94 More over, the self-renewal and tumor-initating capability of GBM-CD133 + treated with localized hyperthermia was significantly blocked. 94 In another study, a bispecific EpCAMxCD3 antibody linking tumor cells and T lymphocytes significantly retarded the tumor growth of BxPC-3 pancreatic carcinoma xenografts. 95 Since CD133 and EpCAM are common surface markers of CSCs, these monoclonal antibodies may also have cytotoxic effects on CSCs.…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%

Therapeutic strategies targeting cancer stem cells

Ning

Shu

et al. 2013

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…Recently, Wang et al further developed singlewalled carbon nanotubes (SWNTs) conjugated with CD133 monoclonal antibody (anti-CD133-SWNTs). 37 The results showed that under irradiation with near-infrared laser light, the in vitro tumorigenic and self-renewal capability of glioblastoma-CD133 + cells were selectively blocked after treatment with anti-CD133-SWNTs, but the glioblastoma-CD133 -cells were barely affected. Significantly, glioblastoma-CD133 …”

Section: Discussionmentioning

confidence: 97%

Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells

Ni¹,

Xiong²,

Zhang³

et al. 2015

IJN

View full text Add to dashboard Cite

Background Cancer stem cells (CSCs) possess the characteristics associated with normal stem cells and are responsible for cancer initiation, recurrence, and metastasis. CD133 is regarded as a CSCs marker of osteosarcoma, which is the most common primary bone malignancy in childhood and adolescence. Salinomycin, a polyether ionophore antibiotic, has been shown to kill various CSCs, including osteosarcoma CSCs. However, salinomycin displayed poor aqueous solubility that hinders its clinical application. The objective of this study was to develop salinomycin-loaded nanoparticles to eliminate CD133 + osteosarcoma CSCs. Methods The salinomycin-loaded PEGylated poly(lactic-co-glycolic acid) nanoparticles (SAL-NP) conjugated with CD133 aptamers (Ap-SAL-NP) were developed by an emulsion/solvent evaporation method, and the targeting and cytotoxicity of Ap-SAL-NP to CD133 + osteosarcoma CSCs were evaluated. Results The nanoparticles are of desired particle size (~150 nm), drug encapsulation efficiency (~50%), and drug release profile. After 48 hours treatment of the Saos-2 CD133 + osteosarcoma cells with drugs formulated in Ap-SAL-NP, SAL-NP, and salinomycin, the concentrations needed to kill 50% of the incubated cells were found to be 2.18, 10.72, and 5.07 μg/mL, respectively, suggesting that Ap-SAL-NP could be 4.92 or 2.33 fold more effective than SAL-NP or salinomycin, respectively. In contrast, Ap-SAL-NP was as effective as SAL-NP, and less effective than salinomycin in Saos-2 CD133 − cells, suggesting that Ap-SAL-NP possess specific cytotoxicity toward Saos-2 CD133 + cells. Ap-SAL-NP showed the best therapeutic effect in Saos-2 osteosarcoma xenograft mice, compared with SAL-NP or salinomycin. Significantly, Ap-SAL-NP could selectively kill CD133 + osteosarcoma CSCs both in vitro and in vivo, as reflected by the tumorsphere formation and proportion of Saos-2 CD133 + cells. Conclusion Our results suggest that CD133 is a potential target for drug delivery to osteosarcoma CSCs and that it is possible to significantly inhibit the osteosarcoma growth by killing CD133 + osteosarcoma CSCs. We demonstrated that Ap-SAL-NP have the potential to target and kill CD133 + osteosarcoma CSCs.

show abstract

Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody

Cited by 168 publications

References 27 publications

The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles

The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles

Therapeutic strategies targeting cancer stem cells

Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells

Contact Info

Product

Resources

About